Shanghai Fosun Pharmaceutical (02196): Ketoprofen patches approved for clinical trials.

Fosun Pharma (02196) announced that its holding subsidiary Shanghai Chaohui Pharmaceutical Co., Ltd. (referred to as "Chaohui Pharmaceutical") recently received approval from the National Medical Products Administration to conduct clinical trials of ketoprofen patch. Chaohui Pharmaceutical plans to conduct Phase III clinical trials of this drug in China when the conditions are met. This drug is a chemical drug primarily used for (1) analgesia and anti-inflammatory effects on the following diseases and symptoms: lumbago (myofascial pain syndrome, degenerative changes of the spine, intervertebral disc disease, and lumbar sprain), osteoarthritis, adhesive capsulitis, tendinitis and tenosynovitis, peritendinitis, lateral epicondylitis (tennis elbow), muscle pain, swelling and pain due to trauma, (2) local pain relief for rheumatoid arthritis.